A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)

  • Tell a FriendPrint

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis...

Brief Summary

Official Title: “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)”

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Intervention(s) in this Clinical Trial

  • Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
  • Drug: Comparator: placebo / Duration of Treatment: 24 weeks

Outcome Measures for this Clinical Trial

Primary Measures

  • Number and average size of rectal polyps
  • Safety and tolerability

Secondary Measures

  • Number and average size of duodenal polyps
  • Proportions of patients with improved overall colon rating

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Males or females at least 18 years of age with familial adenomatous polyposis.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Merck Industry

Overall Clinical Trial Officials and Contacts

Medical Monitor Study Director Merck  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00140894

Study ID Number: 2005_052

ClinicalTrials.gov Identifier: NCT00140894

Health Authority: Canada: Health Canada

  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00140894